The generic drug and over-the-counter health product manufacturer Perrigo Co. (Nasdaq: PRGO) announced that it has agreed to settle its Hatch-Waxman litigation relating to Acetadote (acetylcysteine) injection brought by Cumberland Pharmaceuticals Inc.
The Allegan-based generic drug and health products manufacturer Perrigo Co. (Nasdaq: PRGO) Wednesday reported net income of $106 million or $1.12 a share in the first fiscal quarter ended Sept. 29, up from $70.5 or 75 cents a share in the same quarter a year earlier.
The generic drug and store-brand health and beauty products maker Perrigo Co. (Nasdaq: PRGO) Thursday reported net income fo $393 million or $4.18 a share in its fiscal year ended June 30, up 15 percent from $340.6 million or $3.64 a share in the prior fiscal year.
Perrigo Co. (Nasdaq: PRGO) announced that it has initiated shipments of its Guaifenesin Extended-Release Tablets, 600mg, a generic version of Mucinex 600mg tablets.
Perrigo Co. announced that it has begun shipping Loratadine-D 12 hour extended release tablets, the store brand equivalent to Schering-Plough’s Claritin-D 12 hour extended release tablets.
Perrigo Co. Thursday announced that its Board of Directors declared a quarterly dividend of 8 cents a share.
Perrigo Co. (Nasdaq: PRGO) announced that it has signed a definitive agreement to acquire substantially all of the assets of CanAm Care, a privately-held, Alpharetta, Ga.-based distributor of diabetes care products for approximately $36 million in cash.
Perrigo Co. received final approval from the United States Food and Drug Administration for its Abbreviated New Drug Application for Guaifenesin Extended-Release Tablets, 600 mg.
Perrigo Co. (Nasdaq: PRGO) and its partner Synthon Pharmaceuticals, Inc. today announced that Perrigo has begun shipping Levocetirizine Solution, 2.5 mg/5ml, a generic version of UCB’s Xyzal Oral Solution.
Allegan-based Perrigo Co. Tuesday announced that its partner, PharmaForce-Luitpold Pharmaceuticals, received final approval for Epinastine HCl ophthalmic solution, 0.05 percent, a generic version of Elestat.